Liquidia Corporation
NASDAQ:LQDABiotechnology
+$0.23 today
- Market cap
- $5.08B
- Beta
- 0.59
- P/E (TTM)
- 271.8
- EPS (TTM)
- $0.25
Volume 1.22M
Average 1.50M
LQDA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Liquidia CorporationNASDAQ: LQDA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $74.72M, compared with -$41.58M a year earlier. Trailing-twelve-month net income was $16.82M. Over 3 fiscal years it compounded at +18.9% a year.
Context
- Net income amounted to 43.5% of revenue in FY2025, down 888.1 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$10.62M (-84.6%) for the fiscal year ending Dec 2026, a slowdown from the -47.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $74.72M+208.4% QoQ
- Last fiscal yearDec 2025
- -$68.92M-47.1% YoY
- LTMJun 2026
- $16.82M+111.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +279.7% | +2531.3% | +2251.6 pp |
| 1 year | -47.1% | -84.6% | -37.5 pp |
| 3-year CAGR | +18.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (68.92M) USD
- Year-over-year change
- +47.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.92M) | +47.1% |
| FY2024 | 2024-12-31 | (130.39M) | -66.1% |
| FY2023 | 2023-12-31 | (78.5M) | -91.4% |
| FY2022 | 2022-12-31 | (41.02M) | -18.6% |
| FY2021 | 2021-12-31 | (34.58M) | — |
Net Income vs competitors
How LQDA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +111.9% is the highest of 4, against a peer median of -6.1%.
- Net income amounts to 3.7% of revenue for LQDA, versus a peer median of 76.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.31B USD | +5.5% | +22.4% | 41.6% | |
| LTM Jun 2026 | $875.31M USD | -15.4% | +38.4% | 76.9% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 284.34M SEK | -6.1% | +15.9% | 21379.2% |
| LTM Jun 2026 | $16.82M USD | +111.9% | +18.9% | 3.7% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LQDA) | — | -6.1% | +22.4% | 76.9% | |
Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Depreciation & Amortization | 5.61M | 3.65M | 2.18M | 2.2M | 1.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.75M | 9.3M | 10.09M | 18.81M | 29.47M |
| Change in Working Capital | (12.38M) | (2.16M) | 5.87M | (4.79M) | (24.18M) |
| Accounts Receivables | (2.99M) | (2.03M) | 956K | 1.34M | (51.37M) |
| Inventory | 0 | 0 | 0 | (241K) | (22.99M) |
| Accounts Payables | (7.56M) | 814K | (1.15M) | 2.33M | (2.59M) |
| Other Working Capital | (1.83M) | (945K) | 6.07M | (8.22M) | 52.77M |
| Other Non-Cash Items | 566K | 1.64M | 18.8M | 20.76M | 26.42M |
| Operating Cash Flow | (34.04M) | (28.59M) | (41.56M) | (93.42M) | (35.69M) |
| Capital Expenditures | (107K) | (592K) | (1.29M) | (4.95M) | (4.34M) |
| Acquisitions (Net) | 0 | 5K | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (10M) | (3.49M) | (2M) |
| Investing Cash Flow | (107K) | (587K) | (11.29M) | (8.44M) | (6.34M) |
| Debt Repayment | (420K) | 8.96M | 19.37M | 52.5M | 53.82M |
| Common Stock Issued | 21.71M | 54.46M | 24.24M | 138.55M | 4.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.03M | 1.55M | (363K) | 3.61M | 1.08M |
| Financing Cash Flow | 26.32M | 64.96M | 43.25M | 194.66M | 59.73M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (3.5M) |
| Net Change in Cash | (7.82M) | 35.79M | (9.6M) | 92.8M | 14.2M |
| Free Cash Flow | (34.14M) | (29.18M) | (42.85M) | (98.37M) | (40.02M) |
Liquidia Corporation
NASDAQ:LQDA
Intrinsic Alpha fair value
Locked
Current Price
$56.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.